早期艾司西酞普兰对卒中后抑郁情绪及神经功能的效果:多中心双盲随机安慰剂对照研究
该研究在韩国17个中心纳入急性卒中21天内的患者,随机接受艾司西酞普兰10mg/日或安慰剂治疗3个月。主要终点为中重度抑郁症状(MADRS≥16)频率,结果显示两组在符合方案集和意向治疗分析中均无显著差异。艾司西酞普兰总体耐受良好,腹泻在艾司西酞普兰组更常见。
要点
- 急性卒中后早期使用艾司西酞普兰10mg/日3个月未显著降低中重度抑郁症状频率。
核心结论
- 早期给予艾司西酞普兰并未显著减少急性卒中患者的中重度抑郁症状。
研究设计与样本
- 多中心、双盲、随机、安慰剂对照试验,在韩国17个中心开展。
- 纳入急性卒中21天内的患者,按1:1随机接受口服艾司西酞普兰10mg/日或安慰剂治疗3个月。
- 随机化采用按中心分层的区组置换,通过网络系统完成;共478例患者被分配(安慰剂237例,艾司西酞普兰241例)。
- 全分析集405例(安慰剂195例,艾司西酞普兰210例),为服用研究药物并完成主要终点评估者。
主要发现
- 研究药物总体耐受良好;最常见不良事件为便秘(安慰剂14例[6%] vs 艾司西酞普兰14例[6%])、肌肉疼痛(16例[7%] vs 10例[4%])和失眠(12例[5%] vs 12例[5%])。
- 腹泻在艾司西酞普兰组更常见(9例[4%] vs 2例[1%])。
关键数值与推荐
- 主要终点为中重度抑郁症状频率,定义为蒙哥马利-奥斯伯格抑郁评定量表(MADRS)评分≥16。
- 主要终点在随机化后3个月评估。
临床怎么用
- 对于急性卒中患者,不应仅以预防中重度抑郁症状为目的早期常规使用艾司西酞普兰10mg/日。
- 临床决策需结合患者个体情况,并注意艾司西酞普兰组腹泻更常见。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mood and emotional disturbances are common in patients with stroke, and adversely affect the clinical outcome. We aimed to evaluate the efficacy of early administration of escitalopram to reduce moderate or severe depressive symptoms and improve emotional and neurological dysfunction in patients with stroke. METHODS: This was a placebo controlled, double-blind trial done at 17 centres in South Korea. Patients who had had an acute stroke within the past 21 days were randomly assigned in a 1:1 ratio to receive oral escitalopram (10 mg/day) or placebo for 3 months. Randomisation was done with permuted blocks stratified by centre, via a web-based system. The primary endpoint was the frequency of moderate or severe depressive symptoms (Montgomery-Åsberg Depression Rating Scale [MADRS] ≥16). Endpoints were assessed at 3 months after randomisation in the full analysis set (patients who took study medication and underwent assessment of primary endpoint after randomisation), in all patients who were enrolled and randomly assigned (intention to treat), and in all patients who completed the trial (per-protocol analysis). This trial is registered with ClinicalTrials.gov, number NCT01278498. FINDINGS: Between Jan 27, 2011, and June 30, 2014, 478 patients were assigned to placebo (n=237) or escitalopram (n=241); 405 were included in the full analysis set (195 in the placebo group, 210 in the escitalopram group). The primary outcome did not differ by study group in the full analysis set (25 [13%] patients in the placebo group vs 27 [13%] in the escitalopram group; odds ratio [OR] 1·00, 95% CI 0·56-1·80; p>0·99) or in the intention-to-treat analysis (34 [14%] vs 35 [15%]; OR 1·01, 95% CI 0·61-1·69, p=0·96). The study medication was generally well tolerated; the most common adverse events were constipation (14 [6%] patients who received placebo vs 14 [6%] who received escitalopram), muscle pain (16 [7%] vs ten [4%]), and insomnia (12 [5%] vs 12 [5%]). Diarrhoea was more common in the escitalopram group (nine [4%] patients) than in the placebo group (two [1%] patients). INTERPRETATION: Escitalopram did not significantly reduce moderate or severe depressive symptoms in patients with acute stroke. FUNDING: Dong-A Pharmaceutical and Ministry for Health, Welfare, and Family Affairs, South Korea.
引用
- Kim JS, Lee EJ, Chang DI, et al. Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Psychiatry. 2017. PMID: 28012485. doi:10.1016/S2215-0366(16)30417-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。